Clinical benefit response(CBR)of group A, B and C were 14.8%(4/27),41.5%(17/41)and 50.0%(6/12)in the 3rd month,6.3%(1/16), 21.6%(8/37)and 50.0%(6/12)in the 6th month,respectively.

• 各组临床受益率；第3月时分别为14.；8%25(4/27)、41